Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel vs active comparator in severe GPA/MPA
jRCT2013240076Phase 2Suspended
- Sponsor
- Novartis
- Start
- Mar 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Novartis. Primary endpoint: Event-free survival. Started Mar 2025; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on jRCT2013240076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013240076.